Terminal 4 Communications

About Terminal 4 Communications

T4C is a small-sized virtual company with seasoned healthcare content developers, graphics designers, and project managers located in Belgium, England, the Netherlands, Scotland, and Spain.

We support the development of your regulatory documents for generics, biosimilars, and branded medicines. We also support the dissemination of your product data, product profile, and related therapeutic insights via peer reviewed medical and scientific publications, and at face-to-face and virtual (e.g., advisory boards, congresses) meetings.

Key expertise: COVID-19, H1N1v, HPV, Influenza A, Dengue, Noro Virus, Tick-borne encephalitis, Meningococcal disease, Rabies, ZIKA | Bipolar disorder, Depression, Early onset-, Cognition-, and Negative symptoms of Schizophrenia | DLBCL, Cachexia, Cervical-, Colorectal-, Bladder-, Breast-, Ovarian-, and Prostate cancer, Melanoma, Paediatric cancer | IPF, COPD | Contraception (oral, path, IUD), Menopause (oral, patch), Sexual function, Quality of life | Ischaemic stroke, Duchenne’s Muscular Dystrophy, Multiple sclerosis, Parkinson’s disease.

Our teams are highly dedicated and build a lasting and enjoyable relationship with our clients. These close partnerships are the key to our success and to a great return on their investment.

Since April 2022, we are a proud member of the HealthTribe group of companies. Members of this global agency network work together to provide better cost-effective services based on lean, agile and highly experienced teams that fit a client’s needs.

Skills Not Layers.

Interested to heard more? Call us at +31618217654 or write us at info@t4comms.com

Keywords

• Abstracts
• Cardiovascular
• Congresses
• Copd/Ild
• Ms
• Neurology
• Oncology
• Patient Organisations
• Pharma
• Posters
• Psychiatry
• Regulatory Documents
• Scientific Content Development
• Symposia
• Vaccines
• Women'S Health

Address

• Headquarters

  AmsterdamNoord-Holland, Netherlands

Team by function

Based on 1 public job profiles as of 3 September 2026.

• Executive / C-Suite1